Answers are grounded in this paper and cite their sources.
This study examines the exposure of Medicare Part D beneficiaries to utilization management, such as prior authorization, for oral oncology drugs.
No takes yet. Share an insight, caveat, or question.
Kyle et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: